Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma

Bone Marrow Transplantation, Published online: 25 January 2024; doi:10.1038/s41409-024-02205-6Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma

Source: Bone Marrow Transplantation - January 25, 2024 Category: Hematology Authors: Chiara De Philippis Cristina Zucchinetti Daniele Mannina Mauro Krampera Pier Luigi Zinzani Annalisa Chiappella Alice di Rocco Enrico Orcioulo Maria Chiara Tisi Flavio Pistolese Laura Giordano Armando Santoro Stefania Bramanti Source Type: research